Invivogen
Menu

Anti-hCD20-hIgG1NQ

Anti-hCD20-hIgG1NQ Unit size Cat. code Docs Qty Price
Non-glycosylated monoclonal human IgG1 antibody against human CD20
100 µg
hcd20-mab12
+-
$331.00

Non-glycosylated monoclonal human IgG1 antibody against human CD20

Anti-hCD20-hIgG1NQ features the variable region of rituximab and a mutated constant region of the human IgG1 isotype.
Rituximab is a mouse/human chimeric monoclonal antibody that targets the CD20 antigen found on the surface of malignant and normal B lymphocytes. Binding of rituximab to CD20 results in cell destruction through different mechanisms including direct signaling of apoptosis, complement activation and cell-mediated cytotoxicity. Rituximab has been approved by the FDA for the treatment of various lymphoid malignancies, including B-cell non-Hodgkin's lymphoma and B-cell chronic lymphocytic leukemia.

Anti-hCD20-hIgG1NQ contains a N-glycosylation mutation of the constant region of the human IgG1 where potential asparagine (N) glycosylation sites are substituted by glutamine (Q) residues resulting in the production of a non-glycosylated antibody. Glycosylation of an antibody has no effect on antigen binding but is essential for Fc receptor-mediated activity [1].
In non-glycosylated antibodies the effector mechanisms mediated through the Fc receptors types (FcgRI, FcgRII, FcgRIII) and the C1q component of complement are severely compromised or ablated [2].
Anti-hCD20-hIgG1NQ was generated by recombinant DNA technology. It has been produced in CHO cells and purified by affinity chromatography with protein G.

 

1. Arnold J. et al., 2007. The impact of glycosylation on the biological function and structure of human immunoglobulins. Annu Rev Immunol 25:21-50.
2. Jefferis R., 2009. Glycosylation as a strategy to improve antibody-based therapeutics. Nat Rev Drug
Discov. 8(3):226-34.

Back to the top

Specifications

Clonality: Non-glycosylated Monoclonal antibody

Specificity: Targets cells expressing human CD20

Isotype: Human IgG1

Application :
Anti-hCD20-hIgG1NQ can be compared with anti-hCD20-hIgG1 to study the impact of effector functions.

Quality control

  • The absence of bacterial contamination (e.g. endotoxins and peptidoglycans) is controlled using HEK-Blue™ TLR2 and HEK-Blue™ TLR4 cells.
  • The recognition of human CD20 with this antibody is tested using flow cytometry.
Back to the top

Contents

  • 100 µg purified anti-hCD20-hIgG1NQ antibody, provided azide-free and lyophilized.

Product is shipped at room temperature.

Store lyophilized antibody at -20°C.

Lyophilized product is stable for 1 year

Back to the top

Customer Service
& Technical Support

CAPTCHA
In order to prevent automated spam submissions, please answer the following question:
1 + 0 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Shopping cart is empty